AbstractBook-37-ESGCT 2019 Abstract Book
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: AbstractBook-37-ESGCT 2019 Abstract Book
AbstractBook-37-ESGCT 2019 Abstract Book
ARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book & CELL THERAPYSociedad EspanolaTerapia Génica 'ộ CelularInvited Speaker AbstractsINV016Adenovirus and AAV vectors - Zooming in immunogenicity, vaccination and targetingK Benihoud 1 H Buning 21: CNRS UMR 8203 VcctorolosY and antitumor therapeutics, Villejuif, France; University Paris-Sud. Faculte de AbstractBook-37-ESGCT 2019 Abstract Book s Sciences d'Orsay. Orsay. France 2: Hannover Medical School, Institute of Experiment Hematology, Hannover. GermanyVectors derived from adenoviruses (AbstractBook-37-ESGCT 2019 Abstract Book
Ad) and adeno-associated viruses (AAV) are the most commonly applied DNA-based delivery tools. While Ad have become in particular popular in the fieldARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book s.After recalling the main properties of both kinds of vectors, the presentation will highlight recent advances in the understanding of the molecular bases of their immunogenicity. In particular, we will present the different innate immune pathways activated following the recognition of viral compon AbstractBook-37-ESGCT 2019 Abstract Book ents by specific sensors. Then, we will discuss genetic engineering of the capsid of both vectors and its use for vaccination or targeting purpose.INVAbstractBook-37-ESGCT 2019 Abstract Book
017Delivery of Genome Editing ReagentsM Porteus11: Stanford UniversityWhile genome editing provides a precise ‘hit and run" approach to gene therapy, ARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book onal lecture, I will discuss some of the barriers to successful delivery and approaches that overcome some of these barriers.INV018Precise engineering of mammalian genomesM Guell11: Pompeu Fabra University, BarcelonaOver the last decade, our capacity to engineering genomes has increased significantl AbstractBook-37-ESGCT 2019 Abstract Book y impacting biomedical research and medicine. Despite important progress, mammalian genome engineering still faces important challenges such as limiteAbstractBook-37-ESGCT 2019 Abstract Book
d efficacy, precision and the difficulty to efficiently generate large edits.I will present an overview of new gene editing technologies based on progARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book ties (gene correction, epigenetic editing. RNA modification, multiplex modifications,...).INV019Understanding cellular proliferation and differentiation using single-cell transcriptomicsM Plass1: Centre de Regulació GenòmicaSingle-cell transcriptomics has revolutionized the way we can study the dyna AbstractBook-37-ESGCT 2019 Abstract Book mics of gene regulation and its impact in cell proliferation and differentiation. In a single-cell transcriptomics experiment, we sequence the gene reAbstractBook-37-ESGCT 2019 Abstract Book
pertoire of thousands of cells simultaneously. By comparing the transcriptomic profiles of all these cells computationally, we can capture the dynamicARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book atworm Schmidtea mediterranea. a popular animal model to study adult stem cells in vivo. Our results showed for the first time how stem cells give rise to all possible cell types in an adult animal and identified sets of genes likely involved in regulating this process. More recently, we have used a AbstractBook-37-ESGCT 2019 Abstract Book similar approach to understand the subtle differences that exist at thetranscriptomic level among cells during cell cycle progression. Our preliminarAbstractBook-37-ESGCT 2019 Abstract Book
y results show that many oscillating genes, some known cell cycle regulators, use specific 3' isoforms in different cell cycle phases. These results sARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book generation CAR T cellsH Abken ■■ 1: Regensburg Center for Interventional Immunology (RC1). Chair Gene-Immunotherapy. University Hospital Regensburg, D-93053 Regensburg, GermanyAdoptive therapy with chimeric antigen receptor (CAR) redirected T cells achieved spectacular remissions of refractory leuke AbstractBook-37-ESGCT 2019 Abstract Book mia/lymphoma. the treatment of solid tumors remains so far challenging. In new developments, CAR T cells are used as “living factories” to deposit immAbstractBook-37-ESGCT 2019 Abstract Book
une modulating cytokines in the targeted tumor tissue aiming at converting the immune cell environment into a more favorite one to sustain a productivARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE AbstractBook-37-ESGCT 2019 Abstract Book antigen in the CAR targeted tumor lesion are superior in attracting and activating the innate immune response in the tumor lesion. In a further development a blocking anti-CD30 antibody is integrated into the extracellular CAR domain to prevent CD30L engagement. T cells engineered with an anti-CEA a AbstractBook-37-ESGCT 2019 Abstract Book nd CD30 blocking CAR showed an improved response against CEA+ CD30-negative solid tumors. This new CAR design aims at targeting tumor cells by one scFAbstractBook-37-ESGCT 2019 Abstract Book
v and blocking the CD30/CD30L interaction on the T cell by the other scFv. The strategy thereby combines tumor targeting with preventing repression inARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENE ARCELONA 2019ESGCT 27*ANNUAL CONGRESSIN COLLABORATION WITH SETGYC22-25 OCTOBER 2019 BARCELONA INTERNATIONAL CONVENTION CENTREEUROPEAN SOCIETY OF GENEGọi ngay
Chat zalo
Facebook